

Date: February 12, 2024

Ref. No.: KDL/SE/CI/02/2023-24

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
--	---

Dear Sir/Madam,

**Subject: Outcome of Board Meeting held on February 12, 2024.**

In compliance with Regulation 30 read with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e. February 12, 2024 inter-alia approved and took note of the following items:

- Unaudited (Standalone and Consolidated) Financial Results for the quarter and nine months ended December 31, 2023;
- Formation of a Wholly Owned Subsidiary of the Company;
- Change in Designation of Mr. Yash Prithviraj Mutha (DIN: 07285523) as the Joint Managing Director and Manager of the Company;
- Appointment of Dr. Prashant Pandurangrao Deshmukh (PAN: ALFPD8573K) as a Chief Executive Officer of the Company.
- Resignation of Ms. Pallavi Shantilal Bhatevara (DIN: 03600332) from the position of Managing Director of the Company with effect from close of business hours of March 31, 2024. She will continue as an Executive Director on the Board of the Company;
- Grant of 2,31,766 Options under Krsnaa Employees Stock Option Scheme, 2020.



**Krsnaa Diagnostics Ltd.** (Formerly known as Krsnaa Diagnostics Pvt. Ltd.)

S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station,  
Chinchwad, Taluka - Haveli, Pune, MH - 411019 (India)

020 29780210 / 11 / 12 | info@krsnadiagnostics.com CIN : L74900PN2010PLC138068

Accordingly, kindly find enclosed the following:

- a) Limited Review Report and Unaudited (Standalone and Consolidated) Financial Results for the quarter and nine months ended December 31, 2023.

The Board Meeting commenced at 14:00 Hrs. (IST) and concluded at 21:45 Hrs. (IST)

It is requested to take this intimation on your records.

Thanking you,  
Yours sincerely,

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose  
Company Secretary & Compliance Officer  
Encl: as above



**Independent Auditor's Review Report on unaudited Standalone financial results for the quarter and year to date financial result of Krsnaa Diagnostics Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

**To The Board of Directors of Krsnaa Diagnostics Limited.**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Krsnaa Diagnostics Limited ('the Company') for the quarter ended December 31, 2023 and the year to-date results for the period from April 01, 2023 to December 31, 2023 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



# MSKA & Associates

Chartered Accountants

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates  
Chartered Accountants  
ICAI Firm Registration No.105047W

*SD Khivasara*

**Shraddha D Khivasara**

Partner

Membership No.: 134285

UDIN: *24134285BKEZAB4021*



Place: Pune

Date: February 12, 2024

Statement of Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2023

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2023	September 30, 2023	December 31, 2022	December 31, 2023	December 31, 2022	March 31, 2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income</b>						
	Revenue from operations	1,515.52	1,468.52	1,157.36	4,306.88	3,482.24	4,640.83
	Other income	40.78	41.58	45.51	124.58	134.72	194.10
	<b>Total Income</b>	<b>1,556.30</b>	<b>1,510.10</b>	<b>1,202.87</b>	<b>4,431.46</b>	<b>3,616.96</b>	<b>4,834.93</b>
<b>2</b>	<b>Expenses</b>						
	Cost of material consumed	343.61	359.16	191.89	980.47	484.88	741.79
	Employee benefits expense	261.19	228.18	164.58	685.38	469.94	656.27
	Finance costs	41.39	30.58	22.58	91.51	54.49	76.83
	Depreciation and amortization expense	212.31	194.64	139.03	564.30	391.85	537.82
	Fees to hospitals and others	178.98	181.93	159.16	518.44	637.07	761.63
	Other expenses	350.15	373.78	303.94	1,093.71	898.85	1,238.68
	<b>Total Expenses</b>	<b>1,387.63</b>	<b>1,368.27</b>	<b>981.18</b>	<b>3,933.81</b>	<b>2,937.08</b>	<b>4,013.02</b>
<b>3</b>	<b>Profit before tax (1) - (2)</b>	<b>168.67</b>	<b>141.83</b>	<b>221.69</b>	<b>497.65</b>	<b>679.88</b>	<b>821.91</b>
<b>4</b>	<b>Tax expenses</b>						
	Income Tax charge	27.60	16.97	33.93	82.75	128.23	149.31
	Income Tax charge relating to earlier years	(0.15)	-	0.52	(6.41)	0.52	0.52
	Deferred tax charge/(credit)	5.37	11.78	18.59	19.87	34.13	36.99
	<b>Total tax expenses</b>	<b>32.82</b>	<b>28.75</b>	<b>53.04</b>	<b>96.21</b>	<b>162.88</b>	<b>186.82</b>
<b>5</b>	<b>Profit for the period/year (3) - (4)</b>	<b>135.85</b>	<b>113.08</b>	<b>168.65</b>	<b>401.44</b>	<b>517.00</b>	<b>635.09</b>
<b>6</b>	<b>Other comprehensive income</b>						
	Items that will not be reclassified subsequently to profit and loss:						
	Re-measurement gains on defined benefit plans	3.62	2.16	1.20	7.94	3.54	6.89
	Income tax effect	(0.91)	(0.54)	(0.30)	(1.99)	(0.90)	(1.73)
	<b>Total other comprehensive income for the period/year</b>	<b>2.71</b>	<b>1.62</b>	<b>0.90</b>	<b>5.95</b>	<b>2.64</b>	<b>5.16</b>
<b>7</b>	<b>Total comprehensive income for the period/year, net of tax (5+6)</b>	<b>138.56</b>	<b>114.70</b>	<b>169.55</b>	<b>407.39</b>	<b>519.64</b>	<b>640.25</b>
<b>8</b>	<b>Paid-up equity share capital (Face Value of Rs. 5/- each)</b>	<b>161.45</b>	<b>156.99</b>	<b>156.99</b>	<b>161.45</b>	<b>156.99</b>	<b>156.99</b>
	<b>Other equity</b>						<b>7,268.02</b>
	Earnings per share (Not annualised for periods):						
	Basic (Rs.)	4.28	3.60	5.37	12.74	16.47	20.23
	Diluted (Rs.)	4.16	3.48	5.24	12.33	16.06	19.72



For and on behalf of Board of Directors  
Krsnaa Diagnostics Limited

*P. Bhatevara*

Pallavi Bhatevara  
Managing Director  
DIN: 03600332

Place: Pune

Date: February 12, 2024

**Notes to Unaudited Standalone Financial Results:**

1. These unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 12, 2024.
2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
3. The Company's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Company as one operating segment. Hence, no separate segment information has been furnished herewith.
4. Previous period/year figures have been regrouped/ rearranged wherever considered necessary.

Place: Pune  
Date: February 12, 2024



For and on behalf of Board of Directors  
**Krsnaa Diagnostics Limited**

  
Pallavi Bhatevara  
Managing Director  
DIN: 03600332

**Independent Auditor's Review Report on unaudited Consolidated financial results for the quarter and year to date financial results of Krsnaa Diagnostics Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

**To The Board of Directors Krsnaa Diagnostics Limited**

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Krsnaa Diagnostics Limited** ('the Holding Company') & its subsidiaries (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended December 31, 2023 and the year to-date results for the period from April 01, 2023 to December 31, 2023 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



# MSKA & Associates

Chartered Accountants

4. This Statement includes the results of the Holding Company and the following entities:

Sr. No	Name of the Entity	Relationship with the Holding Company
1	Krsnaa Diagnostics (Mohali) Private Limited	Wholly Owned Subsidiary
2	KDPL Diagnostics (Amritsar) Private Limited	Wholly Owned Subsidiary
3	KDPL Diagnostics (Bathinda) Private Limited	Wholly Owned Subsidiary
4	KDPL Diagnostics (Jalandhar) Private Limited	Wholly Owned Subsidiary
5	KDPL Diagnostics (Ludhiana) Private Limited	Wholly Owned Subsidiary
6	KDPL Diagnostics (Patiala) Private Limited	Wholly Owned Subsidiary
7	KDPL Diagnostics (SAS Nagar) Private Limited	Wholly Owned Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No.105047W

SDKhivasa



**Shraddha D Khivasara**

Partner

Membership No.: 134285

UDIN: 24134285BKEZAC6981

Place: Pune

Date: February 12, 2024



Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2023

(INR Million, except earnings per share)

Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2023	September 30, 2023	December 31, 2022	December 31, 2023	December 31, 2022	March 31, 2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>1</b>	<b>Income</b>						
	Revenue from operations	1,583.22	1,554.49	1,180.98	4,533.50	3,538.97	4,871.23
	Other income	40.78	41.58	45.43	124.58	134.53	193.79
	<b>Total Income</b>	<b>1,624.00</b>	<b>1,596.07</b>	<b>1,226.41</b>	<b>4,658.08</b>	<b>3,673.50</b>	<b>5,065.02</b>
<b>2</b>	<b>Expenses</b>						
	Cost of material consumed	343.61	359.16	191.89	980.47	484.88	741.79
	Employee benefits expense	296.52	264.39	190.43	790.10	534.56	745.64
	Finance costs	41.45	30.63	22.63	91.69	54.61	76.97
	Depreciation and amortization expense	212.31	194.64	139.05	564.30	391.86	537.82
	Fees to hospitals and others	184.01	202.62	164.46	560.49	652.12	812.07
	Other expenses	385.15	410.44	340.12	1,197.00	989.25	1,348.72
	<b>Total Expenses</b>	<b>1,463.05</b>	<b>1,461.88</b>	<b>1,048.58</b>	<b>4,184.05</b>	<b>3,107.28</b>	<b>4,263.01</b>
<b>3</b>	<b>Profit before tax (1) - (2)</b>	<b>160.95</b>	<b>134.19</b>	<b>177.83</b>	<b>474.03</b>	<b>566.22</b>	<b>802.01</b>
<b>4</b>	<b>Tax expenses</b>						
	Income Tax charge	27.60	16.97	33.93	82.75	128.23	149.31
	Income Tax charge relating to earlier years	(0.15)	0.00	0.52	(6.41)	0.52	0.52
	Deferred tax charge/(credit)	3.76	12.26	6.96	16.57	5.54	31.07
	<b>Total tax expenses</b>	<b>31.21</b>	<b>29.23</b>	<b>41.41</b>	<b>92.91</b>	<b>134.29</b>	<b>180.90</b>
<b>5</b>	<b>Profit for the period/year (3) - (4)</b>	<b>129.74</b>	<b>104.96</b>	<b>136.42</b>	<b>381.12</b>	<b>431.93</b>	<b>621.11</b>
<b>6</b>	<b>Other comprehensive income</b>						
	Items that will not be reclassified subsequently to profit and loss:						
	Re-measurement gains on defined benefit plans	3.55	2.07	1.17	7.69	3.52	6.54
	Income tax effect	(0.87)	(0.54)	(0.30)	(1.94)	(0.89)	(1.65)
	<b>Total other comprehensive income for the period/year</b>	<b>2.68</b>	<b>1.53</b>	<b>0.87</b>	<b>5.75</b>	<b>2.63</b>	<b>4.89</b>
<b>7</b>	<b>Total comprehensive income for the period/year, net of tax (5+6)</b>	<b>132.42</b>	<b>106.49</b>	<b>137.29</b>	<b>386.87</b>	<b>434.56</b>	<b>626.00</b>
	<b>Profit/(loss) for the period/year attributable to:</b>						
	Equity Holders of the Holding Company	129.74	104.96	136.42	381.12	431.93	621.11
	Non Controlling Interests	-	-	-	-	-	-
		<b>129.74</b>	<b>104.96</b>	<b>136.42</b>	<b>381.12</b>	<b>431.93</b>	<b>621.11</b>
	<b>Total other comprehensive income/(loss) for the period/year attributable to:</b>						
	Equity Holders of the Holding Company	2.68	1.53	0.87	5.75	2.63	4.89
	Non Controlling Interests	-	-	-	-	-	-
		<b>2.68</b>	<b>1.53</b>	<b>0.87</b>	<b>5.75</b>	<b>2.63</b>	<b>4.89</b>
	<b>Total comprehensive income/(loss) for the period/year attributable to:</b>						
	Equity Holders of the Holding Company	132.42	106.49	137.29	386.87	434.56	626.00
	Non Controlling Interests	-	-	-	-	-	-
		<b>132.42</b>	<b>106.49</b>	<b>137.29</b>	<b>386.87</b>	<b>434.56</b>	<b>626.00</b>
<b>8</b>	<b>Paid-up equity share capital (Face Value of Rs. 5/- each)</b>	<b>161.45</b>	<b>156.99</b>	<b>156.99</b>	<b>161.45</b>	<b>156.99</b>	<b>156.99</b>
	<b>Other equity</b>						<b>7,230.37</b>
	Earnings per share (Not annualised for periods):						
	Basic (Rs.)	4.09	3.35	4.35	12.10	13.76	19.78
	Diluted (Rs.)	3.97	3.23	4.24	11.71	13.42	19.29



For and on behalf of Board of Directors  
Krsnaa Diagnostics Limited

*Pallavi Bhatevara*  
Pallavi Bhatevara  
Managing Director  
DIN: 03600332

**Notes to Unaudited Consolidated Financial Results:**

1. These unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Holding Company at its meeting held on February 12, 2024.
2. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) 2015, as amended.
3. The Group's operations predominantly relate to providing diagnostic services in radiology and pathology services. The Chief Operating Decision Maker (CODM) reviews the operations of the Group as one operating segment. Hence, no separate segment information has been furnished herewith.
4. Previous period/year figures have been regrouped/ rearranged wherever considered necessary.



For and on behalf of Board of Directors  
**Krsnaa Diagnostics Limited**

A handwritten signature in black ink, appearing to read "P. Bhatevara", is written over a faint horizontal line.

Pallavi Bhatevara  
Managing Director  
DIN: 03600332

Place: Pune

Date: February 12, 2024